References

rsp

Научно-практическая ревматология

Rheumatology Science and Practice

1995-44841995-4492

IMA-PRESS, LLC

10.14412/1995-4484-2014-230-237

rsp-1931

Research Article

ИНФОРМАЦИЯ

INFORMATION

Обзор VI научно-образовательного курса EULAR, посвященного системной красной волчанке (Италия, Пиза, 1–6 сентября 2013 г.)

AN OVERVIEW OF THE VI EULAR SCIENTIFIC EDUCATIONAL COURSE DEDICATED TO SYSTEMIC LUPUS ERYTHEMATOSUS (PISA, ITALY, SEPTEMBER 1–6, 2013)

Панафидина

Т. А.

Panafidina

T. A.

panafidina@inbox.ru

ФГБУ «Научно- исследовательский институт ревматологии им. В.А. Насоновой» РАМН, Москва, РоссияРоссияV.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, RussiaRussian Federation

2014

17062014

522

НАУЧНО-ПРАКТИЧЕСКАЯ РЕВМАТОЛОГИЯ 52 No 2-2014

230237

2014

Панафидина Т.А.

Panafidina T.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://rsp.mediar-press.net/rsp/article/view/1931

В статье представлен краткий обзор материалов лекций и практических занятий VI научно-образовательного курса Европейской антиревматической лиги (EULAR), посвященного системной красной волчанке (СКВ), проходившего в начале сентября 2013 г. в итальянском городе Пиза. Целями курса являются обучение моло- дых практикующих ревматологов ранней диагностике, своевременному и адекватному лечению с учетом со- временных представлений об этиопатогенезе СКВ, применению рекомендаций и классификационных кри- териев EULAR, разбор трудных клинических случаев. Основные вопросы данного курса касались пораже- ния нервной системы при СКВ, волчаночного нефрита, терапии традиционными и генно-инженерными биологическими препаратами, ведения беременности при СКВ, необходимости стандартизации методов ди- агностики и лечения этих состояний.

The article presents an overview of the lectures and workshops of the VI scientific educational course by the European League against Rheumatism (EULAR) dedicated to systemic lupus erythematosus (SLE), which was held in Pisa, Italy, in early September 2013. The course aims were to train young practicing rheumatologists to make early diagnosis and provide timely and adequate treatment with allowance for the current concepts of SLE etiopathogenesis; the use of the EULAR recommendations and classification criteria; and analysis of complex clinical cases. The main issues of this course included lesion of the nervous system in SLE, lupus nephritis, therapy with traditional and biological response modifiers, management of pregnancy in SLE patients, the need for standardization of the methods for the diagnosis and treatment of these conditions.

VI научно-образовательный курс EULARсистемная красная волчанкапоражение нервной системы при системной красной волчанкеволчаночный нефритбеременность при системной красной вол- чанкеглюкокортикоидыиммуносупрессанты.

VI EULAR scientific educational coursesystemic lupus erythematosuslesion of the nervous system in systemic lupus erythematosuslupus nephritispregnancy in systemic lupus erythematosusglucocorticoidsimmuno- suppressants.

References1

Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommen- dations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010 Dec;69(12):2074–82. DOI: 10.1136/ard.2010.130476.

Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–7. DOI: http://dx.doi.org/10.1002/art.1780251101

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999 Apr;42(4):599–608. DOI: http://dx.doi.org/10.1002/1529- 0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F.

Petri M, Orbai AM, Alarcоn GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classifi- cation criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677–86. DOI: 10.1002/art.34473.

Popescu A, Kao AH. Neuropsychiatric systemic lupus erythemato- sus. Curr Neuropharmacol. 2011 Sep;9(3):449–57. DOI: 10.2174/157015911796557984.

Unterman A, Nolte JE, Boaz M, et al. Neuropsychiatric syn- dromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011 Aug;41(1):1–11. DOI: 10.1016/j.semarthrit.2010.08.001.

Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and manage- ment of neuropsychiatric SLE manifestations. Nat Rev Rheumatol. 2010 Jun;6(6):358–67. DOI: 10.1038/nrrheum.2010.62. Epub 2010 May 11.

Govoni M. The clinical picture of neuropsychiatric lupus: chal- lenges and critical issues. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.

Luyendijk J, Steens SC, Ouwendijk WJ, et al. Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic reso- nance imaging. Arthritis Rheum. 2011 Mar;63(3):722–32. DOI: 10.1002/art.30157.

Meroni PL. Pathogenesis of CNS involvment in SLE. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.

Bertsias G. EULAR recommendations for neuropsychiatric lupus: pitfalls and challenges. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.

Boumpas DT. EULAR recommendations for lupus nephritis: bal- ancing efficacy vs toxicity, pitfalls, and challenges. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.

Houssiau FA. Treatment of lupus nephritis: old and new approaches. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.

Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association- European Dialysis and Transplant Association (EULAR/ERA- EDTA) recommendations for the management of adult and paedi- atric lupus nephritis. Ann Rheum Dis. 2012 Nov;71(11):1771–82. DOI: 10.1136/annrheumdis-2012-201940. Epub 2012 Jul 31.

Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and man- agement of lupus nephritis. Arthritis Care Res (Hoboken). 2012 Jun;64(6):797–808. DOI: 10.1002/acr.21664.

Moroni G. Clinical and laboratory features of lupus nephritis and prognostic factors. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.

Bijlsma JWJ. Glucocorticoids in SLE: principles of therapy and monitoring. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.

Costedoat-Chalumeau N. Hydroxychloroquine adherence to treatment and SLE. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE; Pisa, Italy. 2013.

Ruiz-Irastorza G. Traditional drugs in SLEfocus on immunosup- pressive drugs. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy. 2013.

Thamer M, Hernan MA, Zhang Y. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009 Mar;36(3):560–4. DOI: 10.3899/jrheum.080828.

Houssiau FA, Isenberg D. Towards treating lupus nephritis without oral steroids: a dream-come-true? Ann Rheum Dis. 2013 Aug;72(8):1271–2. DOI: 10.1136/annrheumdis-2013-203205.

Ding HJ, Gordon C. New biologic therapy for systemic lupus ery- thematosus. Curr Opin Pharmacol. 2013 Jun;13(3):405–12. DOI: 10.1016/j.coph.2013.04.005.

Mosca M. When to use biologic therapies in clinical practice. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.

Rovin BH, Furie R, Latinis K, et al; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012 Apr;64(4):1215–26. DOI: 10.1002/art.34359.

Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythe- matosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan;62(1):222–33. DOI: 10.1002/art.27233.

Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013 Aug;72(8):1280–6. DOI: 10.1136/annrheumdis-2012-202844.

Halpern WG, Lappin P, Zanardi T, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic and toxicologic effects. Toxicol Sci. 2006 Jun;91(2):586–99. DOI: http://dx.doi.org/10.1093/toxsci/kfj148.

Baker KP, Edwards BM, Main SH, et al. Generation and char- acterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253–65.

Navarra SV, Guzman RM, Gallacher AE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-con- trolled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721–31. DOI: 10.1016/S0140-6736(10)61354-2.

Furie R, Petri M, Zamani O, et al.; BLISS-76 Study Group.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec;63(12):3918–30. DOI: 10.1002/art.30613.

Aringer M, Houssiau F, Gordon C, et al. Adverse events and effi-

cacy of TNF-alpha blockade with infliximab in patients with sys- temic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford). 2009 Nov;48(11):1451–4. DOI: 10.1093/rheumatology/kep270.

Merrill JT, Burgos-Vargas R, Westhovens R. The efficacy and safe- ty of abatacept in patients with non-life-threatening manifesta- tions of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Oct;62(10):3077–87. DOI: 10.1002/art.27601.

Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010 Feb;62(2):542–52. DOI: 10.1002/art.27221.

Khamashta M. Therapeutic algorithms for active SLE in pregnan- cy. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy. 2013.

Ruiz-Irastorza G, Khamashta M, Hughes GR. Does SLE flare during pregnancy? Scand J Rheumatol Suppl. 1998;107:76–9.

Оstensen M. Drug therapy and toxicity in pregnancy and lacta- tion. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.

Brucato A. Neonatal lupus. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.

Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: inte- grating clues from the bench and bedside. Eur J Clin Invest. 2011 Jun;41(6):672–8. DOI: 10.1111/j.1365-2362.2010.02443.x.

Sammaritano LR. Therapy insight: guidelines for selection of con- traception in women with rheumatic diseases. Nat Clin Pract Rheumatol. 2007 May;3(5):273–81; quiz 305–6. DOI: http://dx.doi.org/10.1038/ncprheum0484.

Tincani A. Contraception, prevention of infertility and hormonal therapies in SLE. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.

Buyon JP, Petri MA, Kim MY, et al. The effect of combined estro- gen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005 Jun 21;142(12 Pt 1):953–62. DOI: http://dx.doi.org/10.7326/0003-4819-142-12_Part_1-200506210- 00004.

Sanchez-Guerrero J, Gonzalez-Perez M, Durand-Carbajal M, et al. Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum. 2007 Sep;56(9):3070–9. DOI: http://dx.doi.org/10.1002/art.22855.

Moyer VA; U.S. Preventive Services Task Force. Menopausal hor- mone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013 Jan 1;158(1):47–54. DOI: http://dx.doi.org/10.7326/0003-4819-158-1-201301010-00553.

The authors declare that there are no conflicts of interest present.